Bibliographic Details
| Title: |
The Efficacy of Intensive Statin Therapy in Acute Ischemic Stroke Following Intravenous Thrombolysis: The CASE II Study. |
| Authors: |
Chen, Fujian, Zhou, Huan, Zhang, Tingxia, Wang, Liangxue, Chen, Hongfang, Hu, Jin, Xie, Guomin, Yan, Shenqiang, Lou, Min |
| Source: |
CNS Neuroscience & Therapeutics; Jan2025, Vol. 31 Issue 1, p1-7, 7p |
| Subject Terms: |
ISCHEMIC stroke, THROMBOLYTIC therapy, STATINS (Cardiovascular agents), FUNCTIONAL independence measure, NEUROLOGIC manifestations of general diseases, HEALTH outcome assessment, PROPENSITY score matching, ATORVASTATIN |
| Abstract: |
Aims: This study aimed to investigate the efficacy of early intensive statin therapy following intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS). Methods: AIS patients who received IVT and statin therapy were included from multicenter registry databases. The primary endpoint was functional independence, defined by a modified Rankin Scale (mRS) score of 0–2 at 90 days. Propensity score matching (PSM) analyses were employed. Results: A total of 21,349 patients were included in this study, with a mean age of 68.5 ± 12.6 years, of whom 13,578 (63.6%) were male. The baseline NIHSS score was 4 (IQR 2–8). A total of 9532 patients (44.6%) received intensive statin therapy. In the PSM analysis, the proportion of patients with mRS scores of 0–2 was significantly higher in the intensive statin therapy group (OR = 1.095, 95% CI 1.022–1.173, p = 0.010). Statin type modified the effect of intensive statin therapy on functional independence (p‐value for interaction = 0.030). Treatment effects favoring the intensive approach were observed in patients receiving atorvastatin (OR = 1.134, 95% CI 1.051–1.224, p = 0.001). Conclusion: Early intensive statin therapy following IVT leads to a significant but modest improvement in neurological outcomes, particularly in patients treated with atorvastatin as part of the intensive regimen. [ABSTRACT FROM AUTHOR] |
|
Copyright of CNS Neuroscience & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
